Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer

Journal of Clinical Oncology

Volumn 19, Issue 9, 2001, Pages 2527-2533

  Hussain, M ^a   Vaishampayan, U ^a   Du, W ^a   Redman, B ^a   Smith, D C ^a  

^a HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CREATININE; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT CANCER;

EID: 0035339940     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.9.2527     Document Type: Article

References (26)

1. Cancer of the bladder
2. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
3. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors
4. Long term follow up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
5. Carboplatin-based chemotherapy for bladder cancer
6. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
7. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group
8. Phase II trial of paclitaxel plus carboplatin in advanced urothelial tract cancer
9. Paclitaxel plus carboplatin in advanced carcinoma of the urothelial: An active and tolerable outpatient regimen
10. Paclitaxel and carboplatin in patients with metastatic urothelial cancer: Results of a phase II trial
11. Phase II study of Taxol and carboplatin in patients with advanced transitional cell carcinoma of the urothelium: Preliminary results
12. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
13. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer
14. Gemcitabine: A promising new agent in the treatment of advanced urothelial cancer
15. Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: The importance of survival as a clinical trial end point
16. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group study
17. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
18. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clinical Trials Group
19. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: A phase II clinical trial
20. Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: A phase II multicenter trial
21. Ifosfamide paclitaxel and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules
22. A phase I/II study of paclitaxel, cisplatin and gemcitabine in advanced transitional cell carcinoma of the urothelium
23. Gemcitabine and cisplatin versus metotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter phase III study
24. Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy
25. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients
26. Carboplatin-based versus cisplatin based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma